ICU Medical, Inc. announced its financial results for the fourth quarter ended December 31, 2024, reporting total revenues of $629.8 million. This marks an increase from $587.9 million in the same period of the prior year, reflecting continued demand for its medical products.
The company achieved a GAAP gross profit of $227.3 million, resulting in a GAAP gross margin of 36.1%, a notable improvement from 29.2% in Q4 2023. While reporting a GAAP net loss of $(23.8) million, or $(0.97) per diluted share, adjusted diluted earnings per share for Q4 2024 increased to $2.11 from $1.57 in the prior year period, and Adjusted EBITDA reached $105.5 million.
For fiscal year 2025, ICU Medical provided guidance, estimating a GAAP net loss in the range of $(45) million to $(28) million, and GAAP net loss per share between $(1.81) and $(1.11). The company expects adjusted EBITDA (excluding the IV Solutions joint venture impact) to be between $395 million and $425 million, and adjusted EPS between $6.55 and $7.25, with the joint venture anticipated to reduce 2025 adjusted EBITDA by $15 million to $20 million but be neutral to adjusted EPS.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.